SCHEMBL6009426

SCHEMBL6009426

O=S(O)CC(F)CNC1CCc2ccccc2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 6/20 0.53
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
THPO P40225 1/20 0.50
NPC1 O15118 1/20 0.50
MTOR P42345 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
GMNN O75496 1/20 0.49
LMNA P02545 1/20 0.49
PMP22 Q01453 1/20 0.49
PRMT5 O14744 2/20 0.47
MAOA P21397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6009973 0.80 GRIN2B (0.53) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL5510014 0.80 MAOA (0.47) GRIN2BTP53CYP1A2CYP3A4TSHR
SCHEMBL5504382 0.75 KDM4E (0.35) GRIN2BKDM4E
SCHEMBL5510564 0.74 GRIN2B (0.48) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL9536408 0.73 TP53 (0.67) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL5504911 0.73 KDM4E (0.46) GRIN2BCYP1A2CYP2D6KMT2AKDM4E
SCHEMBL9536401 0.72 PRMT5 (0.59) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL17560270 0.71 PRMT5 (0.58) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL14500131 0.71 GRIN2B (0.57) GRIN2BTP53CYP1A2CYP3A4CYP2D6
SCHEMBL6009887 0.71 KDM4E (0.48) CYP1A2CYP2D6KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR GRIN2B 2271/4885TP53 413/4885CYP1A2 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.